Advertisement

Gabapentin Toxicity in Patients with Chronic Kidney Disease: A Preventable Cause of Morbidity

      Abstract

      Background

      Gabapentin is frequently used as an analgesic in patients with chronic kidney disease. Although gabapentin is well known for its favorable pharmacokinetics, it is exclusively eliminated renally, and patients with chronic kidney disease are at risk for toxicity. Existing literature on such risk is lacking.

      Methods

      We examined the Mayo Clinic Rochester database from 1998 to 2007 in patients with serum gabapentin measurements and known medical outcomes. A total of 729 patients were stratified according to their estimated glomerular filtration rate: group I, 126 individuals with estimated glomerular filtration greater than 90 mL/min/1.72 mm3; group II, 594 individuals with estimated glomerular filtration less than 90 mL/min/1.72 mm3 without dialysis; group III, 9 individuals with chronic dialysis.

      Results

      Patients in groups II and III had higher serum gabapentin levels (8.39±0.32 μL/mL and 58.8±10.22 μL/mL, respectively) than in group I (5.52±0.32 μL/mL, P<.01). Toxicity occurred exclusively in groups II (5.56%) and III (77.8%); toxic manifestations were more severe in group III than in group II. Elderly individuals with multiple comorbidities were overrepresented in those with toxic manifestations. Gabapentin toxicity was suspected initially in only 41.5% of symptomatic cases.

      Conclusion

      Gabapentin toxicity in patients with chronic kidney disease is underrecognized. Patients with chronic kidney disease often receive inappropriately high gabapentin dosage for their kidney function, occasioning overt toxicity; advanced age and comorbidity predispose these patients for toxicity. Heightened awareness of such preventable risk, amid the chronic kidney disease epidemic, would be cost-effective and improve healthcare quality.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mathew N.T.
        • Rapoport A.
        • Saper J.
        • et al.
        Efficacy of gabapentin in migraine prophylaxis.
        Headache. 2001; 41: 119-128
        • Nikolajsen L.
        • Finnerup N.B.
        • Kramp S.
        • et al.
        A randomized study of the effects of gabapentin on postamputation pain.
        Anesthesiology. 2006; 105: 1008-1015
        • Caraceni A.
        • Zecca E.
        • Bonezzi C.
        • et al.
        Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.
        J Clin Oncol. 2004; 22: 2909-2917
        • Caraceni A.
        • Zecca E.
        • Martini C.
        • et al.
        Gabapentin for breakthrough pain due to bone metastases.
        Palliat Med. 2008; 22: 392-393
        • Tai Q.
        • Kirshblum S.
        • Chen B.
        • et al.
        Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.
        J Spinal Cord Med. 2002; 25: 100-105
        • Backonja M.
        • Beydoun A.
        • Edwards K.R.
        • et al.
        Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
        JAMA. 1998; 280: 1831-1836
        • Morello C.M.
        • Leckband S.G.
        • Stoner C.P.
        • et al.
        Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.
        Arch Intern Med. 1999; 159: 1931-1937
      1. Huge penalty in drug fraud.
        San Francisco Chronicle. 2004; : C-1
      2. Anticonvulsants: Pfizer's pregabalin to top success of Neuronytin? BioNews.
        (ed: BioPortfolio BioNews)
        • Mula M.
        Anticonvulsants—antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology.
        Curr Drug Metab. 2008; 9: 730-737
        • Bassilios N.
        • Launay-Vacher V.
        • Khoury N.
        • et al.
        Gabapentin neurotoxicity in a chronic haemodialysis patient.
        Nephrol Dial Transplant. 2001; 16: 2112-2113
        • Dogukan A.
        • Aygen B.
        • Berilgen M.S.
        • et al.
        Gabapentin-induced coma in a patient with renal failure.
        Hemodial Int. 2006; 10: 168-169
        • Miller A.
        • Price G.
        Gabapentin toxicity in renal failure: the importance of dose adjustment.
        Pain Med. 2009; 10 (Epub 2008 Aug 18): 190-192
        • Hung T.Y.
        • Seow V.K.
        • Chong C.F.
        • et al.
        Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia.
        Emerg Med J. 2008; 25: 178-179
        • Pierce D.A.
        • Holt S.R.
        • Reeves-Daniel A.
        A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure.
        Clin Ther. 2008; 30: 1681-1684
        • Lipson J.
        • Lavoie S.
        • Zimmerman D.
        Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
        Am J Kidney Dis. 2005; 45: e100-e104
        • Tuccori M.
        • Lombardo G.
        • Lapi F.
        • et al.
        Gabapentin-induced severe myopathy.
        Ann Pharmacother. 2007; 41: 1301-1305
        • Poggio E.D.
        • Wang X.
        • Greene T.
        • et al.
        Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease.
        J Am Soc Nephrol. 2005; 16: 459-466
        • Sagirli O.
        • Cetin S.M.
        • Onal A.
        Determination of gabapentin in human plasma and urine by high-performance liquid chromatography with UV-vis detection.
        J Pharm Biomed Anal. 2006; 42: 618-624
        • Zhu Z.
        • Neirinck L.
        High-performance liquid chromatographic method for the determination of gabapentin in human plasma.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 779: 307-312
      3. MICROMEDEX. Table of Gabapentin Dosage in Renal Failure. In: GPT Dosage in Renal Failure M, gabapentin 1.3.2 and 1.3.5, 2008, ed., 2008.

        • Coresh J.
        • Selvin E.
        • Stevens L.A.
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
        • Wen C.P.
        • Cheng T.Y.
        • Tsai M.K.
        • et al.
        All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan.
        Lancet. 2008; 371: 2173-2182
        • Blum R.A.
        • Comstock T.J.
        • Sica D.A.
        • et al.
        Pharmacokinetics of gabapentin in subjects with various degrees of renal function.
        Clin Pharmacol Ther. 1994; 56: 154-159
        • Catterall W.A.
        Structure and regulation of voltage-gated Ca2+ channels.
        Annu Rev Cell Dev Biol. 2000; 16: 521-555
        • Ji H.Y.
        • Jeong D.W.
        • Kim Y.H.
        • et al.
        Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry.
        Rapid Commun Mass Spectrom. 2006; 20: 2127-2132
        • Johannessen S.I.
        • Battino D.
        • Berry D.J.
        • et al.
        Therapeutic drug monitoring of the newer antiepileptic drugs.
        Ther Drug Monit. 2003; 25: 347-363
        • Brawek B.
        • Loffler M.
        • Dooley D.J.
        • et al.
        Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin.
        Naunyn Schmiedebergs Arch Pharmacol. 2008; 376: 301-307
        • Field M.J.
        • Cox P.J.
        • Stott E.
        • et al.
        Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.
        Proc Natl Acad Sci U S A. 2006; 103: 17537-17542
        • Wong M.O.
        • Eldon M.A.
        • Keane W.F.
        • et al.
        Disposition of gabapentin in anuric subjects on hemodialysis.
        J Clin Pharmacol. 1995; 35: 622-626
        • Krahenbuhl-Melcher A.
        • Schlienger R.
        • Lampert M.
        • et al.
        Drug-related problems in hospitals: a review of the recent literature.
        Drug Saf. 2007; 30: 379-407
        • Bookwalter T.
        • Gitlin M.
        Gabapentin-induced neurologic toxicities.
        Pharmacotherapy. 2005; 25: 1817-1819

      Linked Article

      • Errata
        The American Journal of MedicineVol. 124Issue 10
        • Preview
          Zand L, McKian KP, Qian Q. Gabapentin Toxicity in Patients with Chronic Kidney Disease: A Preventable Cause of Morbidity. Am J Med. 2010;123:367-373.
        • Full-Text
        • PDF